Daré Bioscience Completes Regulation A Preferred Stock Offering

An update from Daré Bioscience ( (DARE) ) is now available.

On March 16, 2026, Daré Bioscience, Inc. closed a previously announced Regulation A offering of investor units priced at $5.00 each, with each unit consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock. In this closing, the company issued 43,050 investor units, representing 43,050 shares of Series A Preferred Stock and warrants to purchase up to 86,100 shares of common stock, reflecting a modest capital raise that adds to its financial resources without fully utilizing the maximum size of the authorized offering.

The most recent analyst rating on (DARE) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Spark’s Take on DARE Stock

According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.

The score is held down primarily by weak financial performance (minimal/declining revenue, ongoing losses, and TTM cash burn) and only modest technical strength (below key moving averages). These are partially offset by a relatively positive earnings call focused on upcoming product launches and a grant-supported pipeline, plus supportive financing and strategic control developments from recent corporate events.

To see Spark’s full report on DARE stock, click here.

More about Daré Bioscience

Daré Bioscience, Inc. is a biopharmaceutical company focused on developing innovative therapies in the healthcare sector, with its activities financed in part through equity and warrant offerings to investors. The company accesses capital markets using structures such as preferred stock and common stock purchase warrants to support its operational and strategic objectives.

Average Trading Volume: 88,980

Technical Sentiment Signal: Strong Sell

Current Market Cap: $21.01M

See more insights into DARE stock on TipRanks’ Stock Analysis page.